Last reviewed · How we verify
1-84 parathyroid hormone
At a glance
| Generic name | 1-84 parathyroid hormone |
|---|---|
| Sponsor | Hvidovre University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Registry for Participants With Chronic Hypoparathyroidism
- HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism (PHASE3)
- A Study of Relative Bioavailability of a New Formulation Compared With the Approved Formulation of rhPTH [1-84] and to Find Out Dose Linearity of the New Formulation in Healthy Adults (PHASE1)
- A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE) (PHASE4)
- A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism (PHASE4)
- Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY) (PHASE3)
- A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in Hungary (PHASE3)
- Use of NPSP558 in the Treatment of Hypoparathyroidism (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 1-84 parathyroid hormone CI brief — competitive landscape report
- 1-84 parathyroid hormone updates RSS · CI watch RSS
- Hvidovre University Hospital portfolio CI